Cargando…
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
Over the past two and a half decades, many clinical trials have been designed to determine the safety and efficacy of pharmacotherapy for patients with idiopathic pulmonary fibrosis (IPF). However, so far, only two drugs (pirfenidone and nintedanib) have been found to have an impact on disease progr...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488742/ https://www.ncbi.nlm.nih.gov/pubmed/28954769 http://dx.doi.org/10.1183/16000617.0071-2017 |